{
 "@context": "https://clearank.com/llms.txt",
 "@type": "clearank:AssetAnalysis",
 "url": "https://clearank.com/stock/moderna-mrna/",
 "dataUrl": "https://clearank.com/stock/moderna-mrna/data.json",
 "title": "Moderna, Inc. (MRNA) Stock Forecast & Price Target (2026)",
 "description": "Moderna Inc. (MRNA) stock: Healthcare, Biotechnology. $54.5B market cap. AI rating, technicals, 2030 forecast and trade plans.",
 "headline": "Moderna Inc. (MRNA)",
 "published": "2026-06-28T09:28:01+00:00",
 "modified": "2026-09-11T17:36:01.518+00:00",
 "generated": "2026-09-11T20:41:08.857Z",
 "language": "en-US",
 "publisher": {
  "name": "CleaRank",
  "url": "https://clearank.com/"
 },
 "disclaimer": "Educational and informational only; not financial advice. AI-generated analysis reviewed by the CleaRank editorial team; prices delayed up to 15 minutes.",
 "asset": {
  "ticker": "MRNA",
  "name": "Moderna Inc.",
  "type": "Common Stock",
  "exchange": "NASDAQ",
  "currency": "USD",
  "sector": "Healthcare",
  "industry": "Biotechnology",
  "country": "United States",
  "website": "https://www.modernatx.com"
 },
 "quote": {
  "price": 148.15,
  "previousClose": 136.62,
  "change": 11.53,
  "changePercent": 8.44,
  "open": 138.035,
  "high": 149.675,
  "low": 135.29,
  "volume": 361598,
  "averageVolume": 14222580,
  "marketCap": 54543607155,
  "fiftyTwoWeekHigh": 176.66,
  "fiftyTwoWeekLow": 22.28,
  "marketOpen": false,
  "asOf": "2026-09-11T17:36:00.000Z"
 },
 "statistics": {
  "pe": -18.59,
  "eps": -7.97,
  "dividendYield": 0,
  "beta": 1.106,
  "priceToSales": 24.480972,
  "priceToBook": 8.062555,
  "revenueTtm": 2228000000,
  "grossMargin": 0.34965034965034963,
  "returnOnEquity": -0.38998002
 },
 "technicals": {
  "rsi": 51.6,
  "macd": 16.96,
  "sma50": 91.12,
  "sma200": 57.15,
  "rsiSignal": "Neutral",
  "trend": "Bullish",
  "pricePosition": "Bullish",
  "macdSignal": "Bullish",
  "rating": "Bullish"
 },
 "analysis": {
  "rating": "Hold",
  "score": 53,
  "consensus": "Hold",
  "fairValue": 148.15,
  "analystTarget": 125,
  "analystCount": 23,
  "wallStreetConsensus": "Hold",
  "generatedAt": "2026-09-11T17:36:00.000Z",
  "priceAtAnalysis": 148.145,
  "volatility": {
   "daily": 32.95,
   "risk": "volatile"
  }
 },
 "tradePlan": {
  "bias": "Neutral",
  "conservativeEntry": 146.66,
  "aggressiveEntry": 148.15,
  "stopLoss": 102.66,
  "stopLossPercent": 30,
  "targets": [
   151.06,
   154,
   158.4
  ]
 },
 "projections": {
  "basis": "Monte Carlo simulation on historical return distribution, re-run daily; not price targets",
  "years": [
   {
    "year": 2027,
    "downside10th": 90.21,
    "base": 171.22,
    "upside90th": 324.98
   },
   {
    "year": 2028,
    "downside10th": 79.96,
    "base": 197.89,
    "upside90th": 489.77
   },
   {
    "year": 2029,
    "downside10th": 75.38,
    "base": 228.71,
    "upside90th": 693.93
   },
   {
    "year": 2030,
    "downside10th": 73.38,
    "base": 264.34,
    "upside90th": 952.25
   },
   {
    "year": 2031,
    "downside10th": 72.9,
    "base": 305.51,
    "upside90th": 1280.31
   },
   {
    "year": 2032,
    "downside10th": 73.49,
    "base": 353.1,
    "upside90th": 1696.6
   },
   {
    "year": 2033,
    "downside10th": 74.9,
    "base": 408.1,
    "upside90th": 2223.65
   },
   {
    "year": 2034,
    "downside10th": 77,
    "base": 471.66,
    "upside90th": 2889.17
   },
   {
    "year": 2035,
    "downside10th": 79.73,
    "base": 545.13,
    "upside90th": 3727.25
   },
   {
    "year": 2036,
    "downside10th": 83.05,
    "base": 630.04,
    "upside90th": 4779.89
   }
  ]
 },
 "faqCount": 7,
 "sources": [
  "TwelveData",
  "Wall Street consensus"
 ],
 "sections": [
  {
   "id": "price",
   "title": "MRNA Price Analysis"
  },
  {
   "id": "market-metrics",
   "title": "Market Metrics",
   "facts": {
    "Open": "$138.04",
    "Day Range": "$135.29 to $149.68",
    "Prev Close": "$136.62",
    "Volume": "361.6K",
    "52-Week Range": "$22.28 to $176.66",
    "Market Cap": "$54.54B"
   }
  },
  {
   "id": "peer-benchmarking",
   "title": "Peer Benchmarking",
   "text": [
    "Sector Position Analysis Valuation is broadly in line with sector peers (-2% difference), suggesting fair market pricing relative to industry standards."
   ]
  },
  {
   "id": "financials",
   "title": "MRNA Financial Performance",
   "text": [
    "Analysis: In the last 4 quarters, MRNA beat estimates 4 times. The stock rose 3 times the next day. Price tends to react positively to beats."
   ]
  },
  {
   "id": "analysis",
   "title": "MRNA Analysis",
   "text": [
    "Moderna Inc. (MRNA) is currently trading above its 50-day SMA ($91.12) and 200-day SMA ($57.15), as well as its 20-day EMA ($129.30), indicating a generally bullish technical posture. The Relative Strength Index (RSI) is at 51.6, suggesting neutral momentum, neither overbought nor oversold. The MACD is positive at 16.96, further supporting the current upward trend. Key support levels are indicated by the moving averages, particularly the 50-day SMA. Resistance levels are less clearly defined by historical data, but the current price action suggests upward momentum could continue in the short term. Volume has been significantly lower than average recently, which could imply less conviction behind recent price movements. Investors should watch for any breaks below the 50-day SMA as a potential signal of weakening momentum.",
    "Insiders have sold $48.3 million worth of stock with no reported purchases, indicating a lack of confidence in near-term price appreciation.",
    "The median Wall Street price target of $125.00 implies a 15.6% downside from the current stock price of $148.15.",
    "Moderna reported an EPS surprise of 4.37% in its most recent quarter ending July 31, 2026, suggesting improving operational performance.",
    "Revenue is expected to grow 8.00% in the current year and 16.00% in the next year, indicating a positive growth trajectory.",
    "Moderna Inc. (MRNA) is expected to see its revenue grow by 8.00% in the current year and accelerate to 16.00% in the next year, suggesting a recovery in its business trajectory. The stock's current trading price above key moving averages indicates positive short-term momentum. However, the median Wall Street price target of $125.00, which is below the current price of $148.15, suggests that analysts believe the stock may be overvalued at present. Potential catalysts for upside could include stronger-than-expected clinical trial results for its pipeline drugs or significant new vaccine approvals. Conversely, downside risks include continued insider selling, a failure to meet revenue growth targets, or increased competition in the biotechnology space. The 'Hold' consensus rating reflects this uncertainty, suggesting investors should await clearer signals before making a significant commitment."
   ],
   "lists": {
    "ProTips": [
     "Monitor insider transaction trends closely; the current 'Moderate Sell Signal' warrants caution.",
     "Given the 'Hold' consensus and downside indicated by the median price target, consider waiting for a clearer entry point or more positive analyst sentiment.",
     "The company's negative EPS makes traditional valuation metrics difficult to apply; focus on revenue growth projections and pipeline developments for future potential."
    ]
   },
   "catalysts": [
    {
     "type": "Bearish",
     "title": "Significant Insider Selling",
     "text": "Insiders have sold $48.3 million worth of stock with no reported purchases, indicating a lack of confidence in near-term price appreciation.",
     "source": "Insider Summary"
    },
    {
     "type": "Bearish",
     "title": "Median Analyst Price Target Suggests Downside",
     "text": "The median Wall Street price target of $125.00 implies a 15.6% downside from the current stock price of $148.15.",
     "source": "Wall Street Summary"
    },
    {
     "type": "Bullish",
     "title": "Positive EPS Surprise in Latest Quarter",
     "text": "Moderna reported an EPS surprise of 4.37% in its most recent quarter ending July 31, 2026, suggesting improving operational performance.",
     "source": "Earnings Recent"
    },
    {
     "type": "Bullish",
     "title": "Projected Revenue Growth",
     "text": "Revenue is expected to grow 8.00% in the current year and 16.00% in the next year, indicating a positive growth trajectory.",
     "source": "Wall Street Revenue Estimates"
    }
   ]
  },
  {
   "id": "key-statistics",
   "title": "Key Statistics",
   "text": [
    "Moderna Inc. (MRNA) presents a mixed fundamental picture, with a current market capitalization of $54.5 billion and negative EPS of -7.97, making traditional P/E ratio analysis inapplicable. Revenue growth is projected to rebound, with an estimated 8.00% increase for the current year and 16.00% for the next, signaling a recovery from previous declines. The company's latest quarterly earnings report showed a positive surprise of 4.37% on EPS, indicating some operational improvements. While the company's revenue growth projections are positive, the negative EPS and the lack of a P/E ratio suggest that valuation is currently driven by future growth expectations rather than current profitability. The median analyst price target of $125.00, which is below the current stock price of $148.15, implies that Wall Street analysts believe the stock is currently overvalued relative to its future prospects and sector averages. Further analysis of the balance sheet and cash flow would be necessary to fully assess its financial health.",
    "Moderna Inc. (MRNA) recently reported earnings with a positive surprise of 4.37% in its latest quarter ending July 31, 2026, with actual EPS of -1.97 against an estimate of -2.06. This follows a pattern of mixed earnings performance, including a significant beat in the May 22, 2026, quarter (32.84% surprise) and another beat in the May 1, 2026, quarter (12.37% surprise). However, the March 17, 2026, quarter showed a miss in price reaction despite a 54.76% EPS surprise. The company's revenue is projected to grow 8.00% in the current year and 16.00% in the next, indicating a path towards recovery.",
    "Moderna Inc. (MRNA) faces several key risks, including a 'Hold' consensus rating from Wall Street and a median price target suggesting a 15.6% downside from current levels. Also, significant insider selling totaling $48.3 million with no corresponding purchases indicates a lack of confidence from management regarding near-term stock appreciation. The company's negative EPS also presents a challenge for traditional valuation metrics, making future growth expectations the primary driver of its stock price."
   ],
   "tables": [
    {
     "caption": "",
     "columns": [],
     "rows": [
      {
       "label": "Market Cap",
       "cells": [
        "54.54B"
       ]
      },
      {
       "label": "P/E Ratio",
       "cells": [
        "N/A (Negative EPS)"
       ]
      },
      {
       "label": "EPS (TTM)",
       "cells": [
        "-7.97"
       ]
      },
      {
       "label": "Dividend Yield",
       "cells": [
        "0.00%"
       ]
      },
      {
       "label": "52 Week High",
       "cells": [
        "176.66"
       ]
      },
      {
       "label": "52 Week Low",
       "cells": [
        "22.28"
       ]
      }
     ]
    }
   ]
  },
  {
   "id": "technical-indicators",
   "title": "Technical Indicators",
   "text": [
    "Technical Rating Bullish RSI Neutral SMA Cross Bullish Price vs SMA Bullish MACD Bullish Golden Cross in effect with the 50-day SMA ($91.12) above the 200-day SMA ($57.15), price action is firmly bullish above key moving averages."
   ],
   "facts": {
    "RSI": "Neutral",
    "SMA Cross": "Bullish",
    "Price vs SMA": "Bullish",
    "MACD": "Bullish"
   },
   "tables": [
    {
     "caption": "",
     "columns": [],
     "rows": [
      {
       "label": "RSI (14)",
       "cells": [
        "51.60"
       ]
      },
      {
       "label": "MACD",
       "cells": [
        "16.96"
       ]
      },
      {
       "label": "SMA 50",
       "cells": [
        "91.12"
       ]
      },
      {
       "label": "SMA 200",
       "cells": [
        "57.15"
       ]
      }
     ]
    }
   ]
  },
  {
   "id": "correlations",
   "title": "Market Correlations",
   "text": [
    "How this stock moves relative to other assets",
    "Based on 1 year of daily price data. Correlations may vary over different time periods."
   ],
   "facts": {
    "Correlation with S&P 500 (SPY)": "+0.29",
    "Correlation with Nasdaq 100 (QQQ)": "+0.26",
    "Correlation with Bitcoin (BTC)": "+0.06",
    "Correlation with Gold (XAU)": "+0.20"
   }
  },
  {
   "id": "trade-plans",
   "title": "MRNA Trade Plans",
   "text": [
    "Specific entry, exit, and risk management levels",
    "Enter now if confident",
    "Volatility-Adjusted Stop Loss Calculated based on RSI (51.6) and current market volatility",
    "Consider scaling out: Take 50% profit at Target 1, 30% at Target 2, let 20% run to Target 3"
   ],
   "facts": {
    "TARGET 1": "$151.06",
    "TARGET 2": "$154.00",
    "TARGET 3": "$158.40",
    "STOP LOSS": "$102.66"
   }
  },
  {
   "id": "seasonality",
   "title": "Seasonal Patterns",
   "text": [
    "Historical monthly performance trends",
    "Based on 3 years of historical monthly returns"
   ],
   "facts": {
    "Average Jan return": "+8.35%",
    "Average Feb return": "+4.65%",
    "Average Mar return": "+0.64%",
    "Average Apr return": "+9.64%",
    "Average May return": "+4.33%",
    "Average Jun return": "+4.10%",
    "Average Jul return": "+5.90%",
    "Average Aug return": "+22.45%",
    "Average Sep return": "-1.04%",
    "Average Oct return": "-1.16%",
    "Average Nov return": "+23.00%",
    "Average Dec return": "-2.94%"
   }
  },
  {
   "id": "risk",
   "title": "Risk & Volatility",
   "facts": {
    "Daily Volatility": "32.95%"
   },
   "lists": {
    "Risk considerations": [
     "Monitor position sizing based on current volatility levels",
     "Consider stop-loss placement beyond recent price range",
     "Diversification helps mitigate single-stock risk exposure"
    ]
   }
  },
  {
   "id": "growth",
   "title": "Growth of $10,000",
   "text": [
    "A $10,000 investment in MRNA in December 2018 would be worth about $73,452 today, compared with about $28,753 for the same investment in the S&P 500 benchmark."
   ]
  },
  {
   "id": "monte-carlo",
   "title": "Monte Carlo Projection (10yr)",
   "text": [
    "CleaRank's 10-year Monte Carlo simulation projects that a $10,000 investment in MRNA today could grow to about $42,529 by 2036 in the base case, with a bull case near $322,650 and a bear case around $5,606. Projections are statistical simulations, not guarantees."
   ]
  },
  {
   "id": "price-prediction",
   "title": "MRNA Stock Price Prediction: 2030",
   "text": [
    "CleaRank's simulation projects a price near $264 for MRNA by 2030 in the base case, from $148 today (1.8x over 4 years). The downside path ends near $73.38. These are outcomes of a Monte Carlo simulation run on MRNA's historical return distribution, not price targets, and they assume no dividends are reinvested.",
    "Method: 10,000 simulated price paths using MRNA's historical volatility and drift, re-run daily. The base case is the median path; the two outer columns are the 10th and 90th percentile outcomes, which widen with time because uncertainty compounds. MRNA is highly volatile, so its upside column reaches an extreme multiple; treat it as a statistical tail, not an expectation. Simulations are not guarantees, and past volatility does not predict future returns. This is analysis, not investment advice."
   ],
   "tables": [
    {
     "caption": "MRNA simulated price paths by year",
     "columns": [
      "Year",
      "Downside (10th pct)",
      "Base case",
      "Upside (90th pct)"
     ],
     "rows": [
      {
       "label": "2027",
       "cells": [
        "$90.21",
        "$171",
        "$325"
       ]
      },
      {
       "label": "2028",
       "cells": [
        "$79.96",
        "$198",
        "$490"
       ]
      },
      {
       "label": "2029",
       "cells": [
        "$75.38",
        "$229",
        "$694"
       ]
      },
      {
       "label": "2030",
       "cells": [
        "$73.38",
        "$264",
        "$952"
       ]
      },
      {
       "label": "2031",
       "cells": [
        "$72.90",
        "$306",
        "$1,280"
       ]
      },
      {
       "label": "2032",
       "cells": [
        "$73.49",
        "$353",
        "$1,697"
       ]
      },
      {
       "label": "2033",
       "cells": [
        "$74.90",
        "$408",
        "$2,224"
       ]
      },
      {
       "label": "2034",
       "cells": [
        "$77.00",
        "$472",
        "$2,889"
       ]
      },
      {
       "label": "2035",
       "cells": [
        "$79.73",
        "$545",
        "$3,727"
       ]
      },
      {
       "label": "2036",
       "cells": [
        "$83.05",
        "$630",
        "$4,780"
       ]
      }
     ]
    }
   ]
  },
  {
   "id": "people-also-watch",
   "title": "People Also Watch",
   "links": [
    {
     "text": "CNC Centene Corp. NYSE $65.40 +2.09%",
     "url": "https://clearank.com/stock/centene-cnc/"
    },
    {
     "text": "VEEV Veeva Systems Inc. NYSE $260.98 +0.0690%",
     "url": "https://clearank.com/stock/veev-stock-analysis/"
    },
    {
     "text": "MDT Medtronic NYSE $90.78 -0.9223%",
     "url": "https://clearank.com/stock/medtronic-mdt/"
    },
    {
     "text": "VRTX Vertex Pharmaceuticals Incorporated NASDAQ $514.56 -1.26%",
     "url": "https://clearank.com/stock/vertex-vrtx/"
    },
    {
     "text": "QDEL QuidelOrtho Corporation NASDAQ $12.15 -3.88%",
     "url": "https://clearank.com/stock/quidelortho-qdel/"
    },
    {
     "text": "RXRX Recursion Pharmaceuticals, Inc. NASDAQ $3.20 +1.11%",
     "url": "https://clearank.com/stock/rxrx-stock-analysis/"
    },
    {
     "text": "OSCR Oscar Health, Inc. NYSE $31.84 +0.2361%",
     "url": "https://clearank.com/stock/oscr-stock-analysis/"
    },
    {
     "text": "CRSP CRISPR Therapeutics AG NASDAQ $52.16 -0.1913%",
     "url": "https://clearank.com/stock/crispr-therapeutics-crsp/"
    }
   ]
  },
  {
   "id": "related-comparisons",
   "title": "Popular Comparisons",
   "links": [
    {
     "text": "LITE vs COHR Comparison Head-to-head analysis →",
     "url": "https://clearank.com/compare/lite-vs-cohr/"
    },
    {
     "text": "V vs MA Comparison Head-to-head analysis →",
     "url": "https://clearank.com/compare/v-vs-ma/"
    },
    {
     "text": "SOFI vs UPST Comparison Head-to-head analysis →",
     "url": "https://clearank.com/compare/sofi-vs-upstart/"
    }
   ]
  },
  {
   "id": "insider-trading",
   "title": "MRNA Insider Trading Analysis",
   "facts": {
    "Bought": "None",
    "Sold": "$48.3M",
    "Insiders": "11",
    "Avg Transaction": "$3.7M"
   },
   "tables": [
    {
     "caption": "Recent insider transactions in MRNA",
     "columns": [
      "Date",
      "Insider",
      "Type",
      "Shares",
      "Value"
     ],
     "rows": [
      {
       "label": "May 13, 2022",
       "cells": [
        "AFEYAN NOUBAR BOGHOS Director",
        "Sell",
        "310.0K",
        "$40.9M"
       ]
      },
      {
       "label": "Jun 11, 2024",
       "cells": [
        "AFEYAN NOUBAR BOGHOS Director",
        "Sell",
        "202.8K",
        "$30.1M"
       ]
      },
      {
       "label": "Aug 5, 2026",
       "cells": [
        "BANCEL STEPHANE J Chief Executive Officer",
        "Sell",
        "499.2K",
        "$28.7M"
       ]
      },
      {
       "label": "Dec 15, 2022",
       "cells": [
        "BANCEL STEPHANE J Chief Executive Officer",
        "Sell",
        "90.0K",
        "$18.8M"
       ]
      },
      {
       "label": "Dec 22, 2022",
       "cells": [
        "BANCEL STEPHANE J Chief Executive Officer",
        "Sell",
        "90.0K",
        "$18.6M"
       ]
      },
      {
       "label": "Aug 4, 2022",
       "cells": [
        "BANCEL STEPHANE J Chief Executive Officer",
        "Sell",
        "90.0K",
        "$17.0M"
       ]
      },
      {
       "label": "Nov 17, 2022",
       "cells": [
        "BANCEL STEPHANE J Chief Executive Officer",
        "Sell",
        "90.0K",
        "$16.5M"
       ]
      },
      {
       "label": "Dec 8, 2022",
       "cells": [
        "BANCEL STEPHANE J Chief Executive Officer",
        "Sell",
        "90.0K",
        "$16.2M"
       ]
      },
      {
       "label": "Dec 29, 2022",
       "cells": [
        "BANCEL STEPHANE J Chief Executive Officer",
        "Sell",
        "90.0K",
        "$16.1M"
       ]
      },
      {
       "label": "Dec 1, 2022",
       "cells": [
        "BANCEL STEPHANE J Chief Executive Officer",
        "Sell",
        "90.0K",
        "$15.9M"
       ]
      }
     ]
    }
   ],
   "links": [
    {
     "text": "SEC Form 4",
     "url": "https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&company=Moderna+Inc.&type=4&dateb=&owner=include&count=40&search_text=&action=getcompany"
    }
   ]
  },
  {
   "id": "faq",
   "title": "Frequently Asked Questions"
  }
 ],
 "faq": [
  {
   "question": "What is Moderna's (MRNA) current stock price and consensus rating?",
   "answer": "Moderna Inc. (MRNA) is currently trading at $148.15 per share. The consensus rating among Wall Street analysts is 'Hold', with a consensus score of 53 out of 100."
  },
  {
   "question": "What is the median analyst price target for Moderna (MRNA) stock?",
   "answer": "The median analyst price target for Moderna (MRNA) is $125.00, which represents a potential downside of 15.6% from its current trading price of $148.15."
  },
  {
   "question": "Are Moderna (MRNA) insiders buying or selling stock?",
   "answer": "Moderna (MRNA) insiders are net sellers of the stock. There have been no reported insider purchases, while total sales amount to $48.3 million in recent filings, indicating a 'Moderate Sell Signal'."
  },
  {
   "question": "What are Moderna's (MRNA) recent earnings performance and future revenue projections?",
   "answer": "Moderna (MRNA) has shown mixed earnings results, with the latest quarter ending July 31, 2026, reporting a positive EPS surprise of 4.37%. Revenue is projected to grow 8.00% in the current year and 16.00% in the next year."
  },
  {
   "question": "How does Moderna's (MRNA) stock performance compare to its sector averages?",
   "answer": "Moderna (MRNA) is trading above its 50-day and 200-day moving averages ($91.12 and $57.15), indicating positive technical momentum. However, its valuation metrics are difficult to assess due to negative EPS. The company's projected revenue growth of 8.00% for the current year is slightly below the Healthcare sector average of 10.00%."
  },
  {
   "question": "What are the main risks facing Moderna (MRNA) stock?",
   "answer": "Key risks for Moderna (MRNA) include the 'Hold' consensus rating, a median price target suggesting downside, significant insider selling, and the challenge of interpreting valuation with negative EPS. These factors highlight potential headwinds for the stock."
  },
  {
   "question": "What is Moderna's (MRNA) stock forecast for 2030?",
   "answer": "Based on Monte Carlo simulations, Moderna's (MRNA) stock forecast for 2030 shows a base case price of $264.34, with a downside projection of $73.38 and an upside projection of $952.25. These are statistical outcomes, not guarantees."
  }
 ],
 "related": {
  "peopleAlsoWatch": [
   {
    "ticker": "CNC",
    "name": "Centene Corp. NYSE",
    "price": "$65.40",
    "change": "+2.09%",
    "url": "https://clearank.com/stock/centene-cnc/"
   },
   {
    "ticker": "VEEV",
    "name": "Veeva Systems Inc. NYSE",
    "price": "$260.98",
    "change": "+0.0690%",
    "url": "https://clearank.com/stock/veev-stock-analysis/"
   },
   {
    "ticker": "MDT",
    "name": "Medtronic NYSE",
    "price": "$90.78",
    "change": "-0.9223%",
    "url": "https://clearank.com/stock/medtronic-mdt/"
   },
   {
    "ticker": "VRTX",
    "name": "Vertex Pharmaceuticals Incorporated NASDAQ",
    "price": "$514.56",
    "change": "-1.26%",
    "url": "https://clearank.com/stock/vertex-vrtx/"
   },
   {
    "ticker": "QDEL",
    "name": "QuidelOrtho Corporation NASDAQ",
    "price": "$12.15",
    "change": "-3.88%",
    "url": "https://clearank.com/stock/quidelortho-qdel/"
   },
   {
    "ticker": "RXRX",
    "name": "Recursion Pharmaceuticals, Inc. NASDAQ",
    "price": "$3.20",
    "change": "+1.11%",
    "url": "https://clearank.com/stock/rxrx-stock-analysis/"
   },
   {
    "ticker": "OSCR",
    "name": "Oscar Health, Inc. NYSE",
    "price": "$31.84",
    "change": "+0.2361%",
    "url": "https://clearank.com/stock/oscr-stock-analysis/"
   },
   {
    "ticker": "CRSP",
    "name": "CRISPR Therapeutics AG NASDAQ",
    "price": "$52.16",
    "change": "-0.1913%",
    "url": "https://clearank.com/stock/crispr-therapeutics-crsp/"
   }
  ],
  "comparisons": [
   {
    "ticker": "LITE vs COHR Comparison",
    "name": "",
    "url": "https://clearank.com/compare/lite-vs-cohr/"
   },
   {
    "ticker": "V vs MA Comparison",
    "name": "",
    "url": "https://clearank.com/compare/v-vs-ma/"
   },
   {
    "ticker": "SOFI vs UPST Comparison",
    "name": "",
    "url": "https://clearank.com/compare/sofi-vs-upstart/"
   }
  ],
  "sectorHub": {
   "text": "Browse all Healthcare →",
   "url": "https://clearank.com/sector/healthcare/"
  },
  "Newly Tracked": [
   {
    "ticker": "ILMN",
    "text": "Illumina Inc.",
    "url": "https://clearank.com/stock/ilmn-stock-analysis/"
   },
   {
    "ticker": "AME",
    "text": "AMETEK, Inc.",
    "url": "https://clearank.com/stock/ame-stock-analysis/"
   },
   {
    "ticker": "VRSK",
    "text": "Verisk Analytics, Inc.",
    "url": "https://clearank.com/stock/vrsk-stock-analysis/"
   },
   {
    "ticker": "DEO",
    "text": "Diageo plc Sponsored",
    "url": "https://clearank.com/stock/deo-stock-analysis/"
   },
   {
    "ticker": "KMB",
    "text": "Kimberly-Clark Corporation",
    "url": "https://clearank.com/stock/kmb-stock-analysis/"
   }
  ],
  "Top Movers (24h)": [
   {
    "ticker": "VET/USD",
    "text": "↑ 7.68%",
    "url": "https://clearank.com/crypto/vet-usd-crypto-analysis/"
   },
   {
    "ticker": "NEAR/USD",
    "text": "↑ 18.46%",
    "url": "https://clearank.com/crypto/near-protocol-near-usd/"
   },
   {
    "ticker": "THETA/USD",
    "text": "↑ 15.25%",
    "url": "https://clearank.com/crypto/theta-network-theta-usd/"
   },
   {
    "ticker": "HPE",
    "text": "↑ 10.41%",
    "url": "https://clearank.com/stock/hewlett-packard-enterprise-hpe/"
   },
   {
    "ticker": "DELL",
    "text": "↑ 10.23%",
    "url": "https://clearank.com/stock/dell-technologies-dell/"
   }
  ],
  "Also in Healthcare": [
   {
    "ticker": "IONS",
    "text": "Ionis",
    "url": "https://clearank.com/stock/ions-stock-analysis/"
   },
   {
    "ticker": "LEGN",
    "text": "Legend Biotech",
    "url": "https://clearank.com/stock/legend-biotech-legn/"
   },
   {
    "ticker": "REGN",
    "text": "Regeneron Pharmaceuticals",
    "url": "https://clearank.com/stock/regeneron-regn/"
   },
   {
    "ticker": "REPL",
    "text": "Replimune",
    "url": "https://clearank.com/stock/repl-stock-analysis/"
   },
   {
    "ticker": "RGNX",
    "text": "REGENXBIO",
    "url": "https://clearank.com/stock/rgnx-stock-analysis/"
   }
  ]
 },
 "schema": [
  {
   "@context": "https://schema.org",
   "@graph": [
    {
     "@type": "Place",
     "@id": "https://clearank.com/#place",
     "address": {
      "@type": "PostalAddress",
      "streetAddress": "Beni Berman 2",
      "addressLocality": "Netanya",
      "addressRegion": "Center",
      "postalCode": "4249330",
      "addressCountry": "IL"
     }
    },
    {
     "@type": "Organization",
     "@id": "https://clearank.com/#organization",
     "name": "CleaRank",
     "url": "https://clearank.com",
     "sameAs": [
      "https://twitter.com/CleaRank",
      "https://www.linkedin.com/company/clearank/",
      "https://www.youtube.com/@CleaRank"
     ],
     "email": "info@clearank.com",
     "address": {
      "@type": "PostalAddress",
      "streetAddress": "Beni Berman 2",
      "addressLocality": "Netanya",
      "addressRegion": "Center",
      "postalCode": "4249330",
      "addressCountry": "IL"
     },
     "logo": {
      "@type": "ImageObject",
      "@id": "https://clearank.com/#logo",
      "url": "https://clearank.com/wp-content/uploads/2025/02/CleaRank-Logo-e1738621466340.jpg",
      "contentUrl": "https://clearank.com/wp-content/uploads/2025/02/CleaRank-Logo-e1738621466340.jpg",
      "caption": "CleaRank",
      "inLanguage": "en-US",
      "width": "336",
      "height": "153"
     },
     "description": "The CleaRank vision is to bring clarity to the online trading industry and protect trader interests. We use our proprietary technology, expert analysis and verified trader insights, to deliver data driven broker evaluations you can trust. Our CLEAR™ Score is our foundation, a transparent, unbiased methodology that assesses brokers and firms based on the most critical factors including regulation, fees, platform reliability, and real user experiences. We are here to change an unfair system and unlike other review sites that are influenced by partnerships or subjective opinions, CleaRank is 100% independent–abiding by our rigorous CLEAR™ editorial code. We do not accept financial incentives from brokers, so what you see is what you get with no hidden agendas, just honest, actionable feedback. Clear data. Honest reviews. That's the CleaRank promise",
     "numberOfEmployees": {
      "@type": "QuantitativeValue",
      "value": "40"
     },
     "location": {
      "@id": "https://clearank.com/#place"
     }
    },
    {
     "@type": "WebSite",
     "@id": "https://clearank.com/#website",
     "url": "https://clearank.com",
     "name": "CleaRank",
     "publisher": {
      "@id": "https://clearank.com/#organization"
     },
     "inLanguage": "en-US"
    },
    {
     "@type": "ImageObject",
     "@id": "https://clearank.com/wp-content/uploads/2026/06/img_moderna-mrna.png",
     "url": "https://clearank.com/wp-content/uploads/2026/06/img_moderna-mrna.png",
     "width": "1280",
     "height": "720",
     "caption": "Moderna (MRNA) stock price analysis chart for June 2026",
     "inLanguage": "en-US"
    },
    {
     "@type": "BreadcrumbList",
     "@id": "https://clearank.com/stock/moderna-mrna/#breadcrumb",
     "itemListElement": [
      {
       "@type": "ListItem",
       "position": "1",
       "item": {
        "@id": "https://clearank.com",
        "name": "Home"
       }
      },
      {
       "@type": "ListItem",
       "position": "2",
       "item": {
        "@id": "https://clearank.com/stock/moderna-mrna/",
        "name": "Moderna, Inc. (MRNA) Stock Price Analysis"
       }
      }
     ]
    },
    {
     "@type": "WebPage",
     "@id": "https://clearank.com/stock/moderna-mrna/#webpage",
     "url": "https://clearank.com/stock/moderna-mrna/",
     "name": "Moderna, Inc. (MRNA) Stock Forecast & Price Target (2026)",
     "datePublished": "2026-06-28T09:28:01+00:00",
     "dateModified": "2026-09-11T17:36:01+00:00",
     "isPartOf": {
      "@id": "https://clearank.com/#website"
     },
     "primaryImageOfPage": {
      "@id": "https://clearank.com/wp-content/uploads/2026/06/img_moderna-mrna.png"
     },
     "inLanguage": "en-US",
     "breadcrumb": {
      "@id": "https://clearank.com/stock/moderna-mrna/#breadcrumb"
     }
    },
    {
     "@type": "Organization",
     "@id": "https://clearank.com/writer/clearank/",
     "name": "CleaRank",
     "description": "CleaRank's vision is to bring clarity to the online trading industry and protecting trader interests by delivering data-driven broker evaluations you can trust.",
     "url": "https://clearank.com/writer/clearank/",
     "image": {
      "@type": "ImageObject",
      "@id": "https://secure.gravatar.com/avatar/4900cf75f960a22a21f1c864e98abc4d5285fa159ea1025d0e8a9db5136e28ef?s=96&d=mm&r=g",
      "url": "https://secure.gravatar.com/avatar/4900cf75f960a22a21f1c864e98abc4d5285fa159ea1025d0e8a9db5136e28ef?s=96&d=mm&r=g",
      "caption": "CleaRank",
      "inLanguage": "en-US"
     },
     "sameAs": [
      "https://clearank.com/",
      "https://twitter.com/CleaRank",
      "https://www.linkedin.com/company/clearank/",
      "https://www.youtube.com/@CleaRank"
     ],
     "worksFor": {
      "@id": "https://clearank.com/#organization"
     },
     "logo": "https://clearank.com/wp-content/uploads/2025/02/CleaRank-Logo-e1738621466340.jpg"
    },
    {
     "@type": "Article",
     "headline": "Moderna, Inc. (MRNA) Stock Forecast & Price Target (2026)",
     "datePublished": "2026-06-28T09:28:01+00:00",
     "dateModified": "2026-09-11T17:36:01+00:00",
     "author": {
      "@id": "https://clearank.com/writer/clearank/",
      "name": "CleaRank"
     },
     "publisher": {
      "@id": "https://clearank.com/#organization"
     },
     "description": "Moderna Inc. (MRNA) stock: Healthcare, Biotechnology. $54.5B market cap. AI rating, technicals, 2030 forecast and trade plans.",
     "name": "Moderna, Inc. (MRNA) Stock Forecast & Price Target (2026)",
     "@id": "https://clearank.com/stock/moderna-mrna/#richSnippet",
     "isPartOf": {
      "@id": "https://clearank.com/stock/moderna-mrna/#webpage"
     },
     "image": {
      "@id": "https://clearank.com/wp-content/uploads/2026/06/img_moderna-mrna.png"
     },
     "inLanguage": "en-US",
     "mainEntityOfPage": {
      "@id": "https://clearank.com/stock/moderna-mrna/#webpage"
     }
    }
   ]
  },
  {
   "@context": "https://schema.org",
   "@type": "FinancialProduct",
   "name": "Moderna Inc. (MRNA)",
   "tickerSymbol": "MRNA",
   "url": "https://clearank.com/stock/moderna-mrna/",
   "description": "AI-powered financial analysis for Moderna Inc. (MRNA) including technical indicators, market metrics, valuation, and price targets - refreshed daily by CleaRank Financial AI.",
   "exchange": "NASDAQ",
   "offers": {
    "@type": "Offer",
    "price": 148.145,
    "priceCurrency": "USD",
    "availability": "https://schema.org/InStock",
    "url": "https://clearank.com/stock/moderna-mrna/",
    "priceValidUntil": "2026-09-12"
   }
  },
  {
   "@context": "https://schema.org",
   "@type": "FAQPage",
   "mainEntity": [
    {
     "@type": "Question",
     "name": "What is Moderna's (MRNA) current stock price and consensus rating?",
     "acceptedAnswer": {
      "@type": "Answer",
      "text": "Moderna Inc. (MRNA) is currently trading at $148.15 per share. The consensus rating among Wall Street analysts is 'Hold', with a consensus score of 53 out of 100."
     }
    },
    {
     "@type": "Question",
     "name": "What is the median analyst price target for Moderna (MRNA) stock?",
     "acceptedAnswer": {
      "@type": "Answer",
      "text": "The median analyst price target for Moderna (MRNA) is $125.00, which represents a potential downside of 15.6% from its current trading price of $148.15."
     }
    },
    {
     "@type": "Question",
     "name": "Are Moderna (MRNA) insiders buying or selling stock?",
     "acceptedAnswer": {
      "@type": "Answer",
      "text": "Moderna (MRNA) insiders are net sellers of the stock. There have been no reported insider purchases, while total sales amount to $48.3 million across 82 transactions, indicating a 'Moderate Sell Signal'."
     }
    },
    {
     "@type": "Question",
     "name": "What are Moderna's (MRNA) recent earnings performance and future revenue projections?",
     "acceptedAnswer": {
      "@type": "Answer",
      "text": "Moderna (MRNA) has shown mixed earnings results, with the latest quarter ending July 31, 2026, reporting a positive EPS surprise of 4.37%. Revenue is projected to grow 8.00% in the current year and 16.00% in the next year."
     }
    },
    {
     "@type": "Question",
     "name": "How does Moderna's (MRNA) stock performance compare to its sector averages?",
     "acceptedAnswer": {
      "@type": "Answer",
      "text": "Moderna (MRNA) is trading above its 50-day and 200-day SMAs, indicating positive technical momentum. However, its valuation metrics are difficult to assess due to negative EPS. The company's projected revenue growth of 8.00% for the current year is slightly below the Healthcare sector average of 10.00%."
     }
    },
    {
     "@type": "Question",
     "name": "What are the main risks facing Moderna (MRNA) stock?",
     "acceptedAnswer": {
      "@type": "Answer",
      "text": "Key risks for Moderna (MRNA) include the 'Hold' consensus rating, a median price target suggesting downside, significant insider selling, and the challenge of interpreting valuation with negative EPS. These factors highlight potential headwinds for the stock."
     }
    },
    {
     "@type": "Question",
     "name": "What is Moderna's (MRNA) stock forecast for 2030?",
     "acceptedAnswer": {
      "@type": "Answer",
      "text": "Based on Monte Carlo simulations, Moderna's (MRNA) stock forecast for 2030 shows a base case price of $264.34, with a downside projection of $73.38 and an upside projection of $952.25. These are statistical outcomes, not guarantees."
     }
    }
   ]
  }
 ]
}